Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Operating activities:
Net loss	$ (242,999)	$ (130,805)
Reconciliation of net loss to net cash used in operating activities:
Depreciation and amortization	9,678	10,012
Equity-based compensation	43,077	42,640
Other non-cash items, net	(16,566)	(5,620)
Acquired in-process research and development	0	1,500
Changes in:
Accounts receivable	200,000	(70,000)
Prepaid expenses and other assets	5,297	15,952
Accounts payable and accrued expenses	18,724	13,637
Deferred revenue	(775)	0
Operating lease assets and liabilities	(1,874)	(1,277)
Other liabilities, net	(392)	(485)
Net cash provided by (used in) operating activities	14,170	(124,446)
Investing activities:
Purchase of property, plant and equipment	(1,428)	(6,614)
Purchase of in-process research and development	0	(1,500)
Investment in equity securities	(12,885)	0
Purchases of marketable securities	(797,509)	(452,363)
Maturities of marketable securities	587,117	795,229
Net cash (used in) provided by investing activities	(224,705)	334,752
Financing activities:
Proceeds from issuance of common shares, net of issuance costs	279,733	0
Proceeds from exercise of options and ESPP contributions, net of issuance costs	25,735	22,169
Net cash provided by financing activities	305,468	22,169
Effect of exchange rate changes on cash	(9)	60
Increase in cash	94,924	232,535
Cash, cash equivalents and restricted cash, beginning of period	401,068	224,060
Cash, cash equivalents and restricted cash, end of period	495,992	456,595
Supplemental disclosure of non-cash investing and financing activities
Property and equipment purchases in accounts payable and accrued expenses	20	1,029
Equity issuance costs in accounts payable, accrued expenses, and other long term liabilities	$ 3,029	$ 293